Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul:132:108-117.
doi: 10.1016/j.ijid.2023.03.050. Epub 2023 Apr 6.

Evolution of Plasmodium falciparum antimalarial drug resistance markers post-adoption of artemisinin-based combination therapies in Yaounde, Cameroon

Peter Thelma Ngwa Niba  1 , Akindeh Mbuh Nji  1 , Jean Paul Kengne Chedjou  2 , Helle Hansson  3 , Emma Filtenborg Hocke  3 , Innocent Mbulli Ali  4 , Olivia Achonduh-Atijegbe  5 , Marie-Solange B Evehe  5 , Marie Helene Munck Jørgensen  3 , Calvino Tah Fomboh  1 , Liwang Cui  6 , Gillian Stresman  7 , Jude D Bigoga  1 , Michael Alifrangis  3 , Wilfred F Mbacham  8
Affiliations

Evolution of Plasmodium falciparum antimalarial drug resistance markers post-adoption of artemisinin-based combination therapies in Yaounde, Cameroon

Peter Thelma Ngwa Niba et al. Int J Infect Dis. 2023 Jul.

Abstract

Objectives: This study aimed to investigate the evolution of Plasmodium falciparum antimalarial drug resistance markers by comparing the pre- and post-adoption of artemisinin-based combination therapies (ACTs) in Yaounde, Cameroon.

Methods: The molecular characterization of known antimalarial drug resistance markers (Pfcrt, Pfmdr1, Pfdhfr, Pfdhps, and Pfk13) in P. falciparum-positive samples collected in 2014 and 2019-2020 was achieved using nested polymerase chain reaction, followed by targeted amplicon deep sequencing on the Illumina MiSeq platform. Data derived were compared with those published during the pre-ACT adoption period from 2004 to 2006.

Results: A high prevalence of Pfmdr1 184F, Pfdhfr 51I/59R/108N, and Pfdhps 437G mutant alleles was observed during the post-ACT adoption period. The Pfcrt 76T and Pfmdr1 86Y mutant alleles significantly declined between 2004 and 2020 (P <0.0001). Conversely, the resistance markers to antifolates, Pfdhfr 51I/59R/108N and Pfdhps 437G, significantly increased during the same study period (P <0.0001). We identified nine mutations in the propeller domains of Pfk13; although they were all present in single parasite isolates, none of them are known to confer artemisinin resistance.

Conclusion: This study documented a near-complete reversion to sensitive parasites for markers conferring resistance to the 4-aminoquinolines and arylamino alcohols in Yaounde. In contrast, the Pfdhfr mutations associated with pyrimethamine resistance are moving toward saturation.

Keywords: Artemisinin-based combination therapies; Cameroon; Drug resistance; Evolution; Plasmodium falciparum; Targeted amplicon deep sequencing.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors have no competing interests to declare.

Figures

Figure 1
Figure 1
Study profile of enrolled participants. AL, artemether-lumefantrine; AQ, amodiaquine; AS-AQ, artesunate-amodiaquine; NGS, next generation sequencing; PCR, polymerase chain reaction; Pfcrt, Plasmodium falciparum chloroquine resistance transporter gene (mutations at position C72S, V73K, M74I, N75E, and K76T); Pfmdr1, P. falciparum multidrug resistance 1 gene (mutations at position N86Y, Y184F, S1034C, N1042D, and D1246Y); Pfdhfr, P. falciparum dihydrofolate reductase gene (mutations at position Pfdhfr A16V, C50R, N51I, C59R, S108N/T, and I164L); Pfdhps, P. falciparum dihydropteroate synthase gene; (mutations at position I431V, S436A/F, A437G, K540E/N, A581G, and A613S/T); Pfk13, P. falciparum kelch 13 gene (mutations in the nonpropeller and propeller regions); SP, sulfadoxine-pyrimethamine; SP-AQ, sulfadoxine-pyrimethamine-amodiaquine; SSOP, sequence specific oligonucleotide probe.
Figure 2
Figure 2
Evolution of antimalarial drug policy in Yaounde, Cameroon (2002-2014). AL, artemether-lumefantrine; AQ, amodiaquine; AS-AQ, artesunate-amodiaquine; CQ, chloroquine; MD, microscopy diagnosis; PD, presumptive diagnosis; RDT, rapid diagnostic test; SP, sulfadoxine-pyrimethamine.
See this image and copyright information in PMC

References

    1. World Health Organization (WHO). World malaria report 2022, https://www.who.int/publications/i/item/9789240064898; 2022 [accessed 06 January 2023].
    1. Cameroon National Malaria . Control Program (NMCP) annual report of activities. 2006.
    1. Pearce RJ, Pota H, Evehe MSB, Bâ EH, Mombo-Ngoma G, Malisa AL, et al. Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Med. 2009;6 doi: 10.1371/journal.pmed.1000055. - DOI - PMC - PubMed
    1. Uwimana A, Legrand E, Stokes BH, Ndikumana JM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602–1608. doi: 10.1038/s41591-020-1005-2. - DOI - PMC - PubMed
    1. World Health Organization . World Health Organization; Geneva: 2021. World malaria report 2021.

MeSH terms